Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:18 PM
Ignite Modification Date:
2026-03-26 @ 3:18 PM
NCT ID:
NCT07321067
Eligibility Criteria:
Inclusion Criteria:
* Adults (≥18 years) with radiologically or histologically confirmed advanced HCC
* Candidates for systemic immune checkpoint inhibitors (e.g., atezolizumab-bevacizumab, durvalumab-tremelimumab).
* Patients with preserved liver function. ( up to G2 using ALBI score or up to B (7 ) using Child-Pugh socring system) .
Exclusion Criteria:
* Child-Pugh C liver function.
* Prior liver transplantation.
* patients with concurrent malignancies other than HCC.
* Active autoimmune disease requiring systemic immunosuppression.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07321067
Study Brief:
Protocol Section:
NCT07321067